Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

已完结 10 由 000 发布于 2025/3/3 15:24:19

DOI:10.1136/ard-2023-225445
作者：Tina Baker, Hoda Sharifian, Paul J Newcombe, Patrick G Gavin, Mark N Lazarus, Madhu Ramaswamy, Wendy I White, Nicola Ferrari, Daniel Muthas, Raj Tummala, Eric F Morand, Richard Furie, Edward M Vital,
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Introduction Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网基于遥感数据差分融合的苹果园树冠氮素含量反演